Contrasting Guided Therapeutics (GTHP) and The Competition

Guided Therapeutics (OTCMKTS:GTHP) is one of 74 publicly-traded companies in the “Electromedical equipment” industry, but how does it compare to its rivals? We will compare Guided Therapeutics to related businesses based on the strength of its risk, dividends, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Earnings and Valuation

This table compares Guided Therapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Guided Therapeutics	$100,000.00	-$3.49 million	-5.83
Guided Therapeutics Competitors	$1.04 billion	$89.46 million	-7.33

Guided Therapeutics’ rivals have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current recommendations for Guided Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
Guided Therapeutics Competitors	269	802	2008	109	2.61

As a group, “Electromedical equipment” companies have a potential upside of 3,139.56%. Given Guided Therapeutics’ rivals higher probable upside, analysts plainly believe Guided Therapeutics has less favorable growth aspects than its rivals.

Insider & Institutional Ownership

9.7% of Guided Therapeutics shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Electromedical equipment” companies are owned by institutional investors. 66.8% of Guided Therapeutics shares are owned by insiders. Comparatively, 14.5% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Guided Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-138.23%
Guided Therapeutics Competitors	-331.29%	-92.21%	-30.02%

Risk and Volatility

Guided Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ rivals have a beta of 17.29, suggesting that their average share price is 1,629% more volatile than the S&P 500.

Summary

Guided Therapeutics rivals beat Guided Therapeutics on 6 of the 10 factors compared.

About Guided Therapeutics

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.